Diagnostic Test Development and Production for Emergency Response
ID: 75D301-25-R-73207Type: Combined Synopsis/Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFCENTERS FOR DISEASE CONTROL AND PREVENTIONCDC OFFICE OF ACQUISITION SERVICESATLANTA, GA, 30333, USA

NAICS

Testing Laboratories and Services (541380)

PSC

SUPPORT- PROFESSIONAL: OTHER (R499)

Original Source

https://sam.gov/opp/8da29c2cec7e4532ac9f0f439b12375d/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking contractors for the development and production of diagnostic tests aimed at enhancing emergency response capabilities for public health threats. The procurement involves a range of tasks, including the rapid development and validation of Nucleic Acid Amplification Tests for selected pathogens, regulatory submissions for Emergency Use Authorization (EUA) or 510(k) approval, and the manufacturing of tests to meet outbreak demands. This initiative is critical for bolstering the national laboratory system's readiness and efficiency in addressing public health emergencies. Proposals are due by December 2, 2024, with a maximum contract value of $148 million and a minimum order of $10,000. Interested parties can contact Shayna Connery at xvj9@cdc.gov or (404) 498-0715 for further information.

    Point(s) of Contact
    Shayna Connery
    (404) 498-0715
    xvj9@cdc.gov
    Austin Pagliaccetti
    (770) 488-5472
    zsm6@cdc.gov
    Files
    Title
    Posted
    75D301-25-R-73207 Combined Synopsis and Solicitation Final.pdf
    The document outlines a solicitation by the Centers for Disease Control and Prevention (CDC) for the development and production of diagnostic tests in response to public health emergencies. It is a Request for Proposal (RFP) identified as 75D301-25-R-73207, issued on November 7, 2024, with proposals due by December 2, 2024. The CDC plans to award multiple Indefinite Delivery Indefinite Quantity (IDIQ) contracts, emphasizing firm-fixed price and cost-reimbursable task orders for laboratory testing services, development of diagnostic methods, and regulatory submissions. The RFP specifically targets laboratory testing and test development services, aiming to enhance the national laboratory system's efficiency and readiness. Offerors are encouraged to submit proposals that include a completed Offeror Representations and Certifications and respond to all outlined contract clauses related to federal regulations. The maximum contract value is set at $148 million, with a minimum order of $10,000. The solicitation incorporates numerous Federal Acquisition Regulation clauses to ensure compliance and outlines the processes for submitting questions and proposals. The document underscores the government’s intent to bolster public health infrastructure through competitive procurement while ensuring adherence to required standards and practices.
    Pricing Table (Protected).xlsx
    The document outlines a pricing table for diagnostic testing initiatives associated with the development and validation of diagnostic tests for selected pathogens. It comprises various tasks, including the creation of a Diagnostic Development and Validation Plan, optimizing test sensitivity and specificity, and manufacturing tests. Notably, it mentions producing tests in response to outbreaks and the submission of a validation data package to the FDA for Emergency Use Authorization (EUA) or 510(k) approval. Costs for various tasks over multiple years are specified, indicating a structured approach to budget allocation. The table includes subtasks for test validation, differentiating between situations where pathogen samples are sourced in advance or during an outbreak. The aim of these efforts is to ensure readiness for public health challenges, hinting at cooperation with the CDC for resources and data. This document fits within federal RFPs and grant proposals, highlighting the government's proactive stance on public health emergencies through efficient funding and resource allocation for diagnostic testing capabilities.
    Lifecycle
    Title
    Type
    Diagnostic Test Development and Production for Emergency Response
    Currently viewing
    Combined Synopsis/Solicitation
    Similar Opportunities
    RISER Meet and Greet
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is seeking qualified large businesses under NAICS 325413, In-Vitro Diagnostic Substance Manufacturing, to participate in the RISER Meet and Greet initiative aimed at enhancing public health surveillance and laboratory capacity. This opportunity is part of a phased approach to identify capable businesses that can provide diagnostic and testing services, ultimately expanding the CDC's inventory of reference pathogens and detection kits for rapid response during public health emergencies. Interested parties must respond by November 14, 2024, with their capabilities and relevant past performance, as the virtual meet-and-greet conference is scheduled for December 11, 2024. For further inquiries, interested businesses can contact Jennifer Gartzke at jgartzke@cdc.gov or call 404-498-0020.
    CDC DFWED NARST Sensititre Supplies
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is seeking to award a sole source contract for antimicrobial resistance testing supplies, specifically Sensititre™ broth microdilution testing products, from ThermoFisher Scientific. This procurement is essential for the National Antimicrobial Resistance Monitoring System (NARMS), which has utilized these proprietary materials since 1996 to ensure a standardized approach to monitoring enteric bacteria resistance. The unique nature of these supplies necessitates this sole source approach, as alternatives would require significant investments in new equipment and validation processes, potentially disrupting critical surveillance efforts. Interested parties may respond within 15 days to express their interest, with proposals directed to contract specialist Ashley Williams at dal3@cdc.gov.
    Serological Assays for the detection and characterization of influenza viruses
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking contractors for the provision of serological assays aimed at detecting and characterizing influenza viruses. This contract encompasses a 12-month base period with four additional 12-month option periods, focusing on testing immunological responses from human samples collected during vaccine effectiveness studies, randomized controlled trials, and outbreak investigations using Hemagglutination Inhibition (HAI) assays. The services are critical for understanding vaccine efficacy and managing influenza outbreaks, with the government supplying necessary standard operating procedures, proficiency panels, and controls to ensure proper assay performance. Interested parties should contact Jennifer Gartzke at jgartzke@cdc.gov or 404-498-0020 for further details, as this opportunity is set aside for small businesses under the SBA guidelines.
    6550--NEW - Covid Testing - Base + 2
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to award a sole source contract to Cepheid for the provision of 510K/FDA approved COVID-19 testing supplies, specifically the Cepheid Xpress COV-2/Flu/RSV Plus and Xpress COVID Plus tests. This procurement involves a Firm-Fixed price, Indefinite Delivery Indefinite Quantity (IDIQ) contract that includes a base year and two additional ordering periods, with the vendor required to provide educational materials and ensure compliance with health regulations while communicating any supply shortages. The exclusive procurement from Cepheid is justified by their unique capability to meet the VA's requirements efficiently, emphasizing the importance of timely COVID-19 testing solutions for veterans and healthcare staff. Interested parties may submit capability statements or proposals for consideration, but if no responses are received within seven days, the contract will be awarded to Cepheid. For further inquiries, contact Susan Flores at Susan.flores2@va.gov or (210) 694-6227.
    BIOFIRE Defense, LLC Test Kits and Reagents
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a fixed-price contract to BioFire Defense, LLC for the provision of BIOFIRE® Reagent Kits and associated test kits. The procurement aims to secure proprietary test kits and reagents essential for the NIH Clinical Center's Department of Laboratory Medicine, which supports patient care and research by detecting pathogens in various patient specimens, including blood and respiratory samples. The BioFire test kits are critical for rapid diagnostics, allowing clinicians to initiate timely treatment for infections, and BioFire Defense, LLC is the sole source for these products due to compatibility requirements with government-owned analyzers. Interested parties capable of providing similar products may submit capability statements by November 17, 2024, at 12:00 PM EST to Sheri Eiri at sheri.eiri@nih.gov.
    Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking proposals for the "Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability" through a Special Notice. The objective of this procurement is to establish a long-term partnership focused on developing a flexible and rapid response capability for vaccine development against pandemic influenza and other priority pathogens, initially emphasizing influenza mRNA vaccine development. This initiative is critical for enhancing the nation's preparedness and response to emerging infectious diseases, ensuring readiness to pivot quickly in the face of public health threats. Interested parties can access the full Request for Project Proposals and additional consortium information at www.rrpv.org, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.
    Adult Flu Vaccines 2025-2026
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is soliciting proposals for Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts to procure adult influenza vaccines for the 2025-2026 season. The procurement aims to utilize Section 317 vaccine purchase funds to provide state and local health departments with access to vaccines at favorable prices, particularly targeting populations at higher risk of under-vaccination. This initiative includes a minimum order of 100 doses and a maximum of 6 million doses, with strict compliance to FDA standards and specific delivery requirements. Proposals are due by November 12, 2024, and interested parties should direct inquiries to Matheu Wilson at zlb4@cdc.gov or David Dombeck at vwj8@cdc.gov. The contract period will extend from the date of award through February 28, 2026.
    Pediatric Flu Vaccine – 2025-2026
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is seeking proposals for the procurement of pediatric influenza vaccines for the 2025-2026 season under solicitation number 75D301-25-R-73215. The CDC requires one or more indefinite quantity, indefinite delivery contracts for the purchase of vaccines specifically for children aged 0 through 18 years, with a minimum order size of 100 doses and a maximum of 30 million doses, to support immunization programs under the Vaccine for Children (VFC) program. This initiative is crucial for enhancing public health by ensuring the availability of quality vaccines to reduce healthcare costs associated with preventable diseases. Proposals are due by November 12, 2024, and interested parties should direct inquiries to Matheu Wilson at zlb4@cdc.gov or David Dombeck at vwj8@cdc.gov.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 NIAID DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing medical countermeasures against infectious diseases. This opportunity encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant pathogens, and the creation of direct acting antivirals targeting viruses with pandemic potential. The initiative is critical for enhancing public health responses to emerging infectious threats and includes funding estimates of up to $8.5 million for Research Area 001 and $20 million for Research Area 002, with proposals due to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) platform, starting around November 22, 2024. For further inquiries, interested parties may contact Swee L. Teo at teosl@niaid.nih.gov or Brian Madgey at brian.madgey@nih.gov.
    BIO-RAD LABORATORIES, INC. CSP, QX200 DIGITAL PCR W/ADG OS DIGITAL PCR SYSTEMS W/AUTO DG SERVICE CONTRACT
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is planning to award a sole source fixed-price contract to Bio-Rad Laboratories, Inc. for a service contract related to two QX200 AutoDG ddPCR Systems. The contract will cover a twelve-month base year with four additional option years, focusing on essential maintenance and support services to ensure compliance with FDA regulations and optimal operational performance of the equipment. These systems are critical for assessing gene modification efficiency in cellular therapy products, which directly impacts treatment decisions and patient outcomes. Interested parties may express their interest and capabilities to Tasha Lowe at lowet2@mail.nih.gov by November 9, 2024, at 12 PM, as the government retains discretion over the procurement process.